MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 833-838

  Tang, Mingjie ^a   Lin, Lijun ^b   Cai, Haikang ^c   Tang, Jie ^c   Zhou, Zubin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Xuhui Central Hospital   (China)

Author keywords

Disease free survival; miR 145; Osteosarcoma; Overall survival; Prognosis

Indexed keywords

MICRORNA 145;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH;

EID: 84880121931     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S40080     Document Type: Article

References (27)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3-13.
2. Teicher BA. Searching for molecular targets in sarcoma. Biochem Pharmacol. 2012;84(1):1-10.
3. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467-478.
4. Osman A. MicroRNAs in health and disease-basic science and clinical applications. Clin Lab. 2012;58(5-6):393-402.
5. Izzotti A. Molecular medicine and the development of cancer chemopreventive agents. Ann N Y Acad Sci. 2012;1259:26-32.
6. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. MicroRNAs in cancer management. Lancet Oncol. 2012;13(6):e249-e258.
7. Cho WC. Great potential of miRNAs as predictive and prognostic markers for cancer. Expert Rev Mol Diagn. 2012;12(4):315-318.
8. Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma. Sarcoma. 2012;2012:359739.
9. Xu Q, Liu LZ, Qian X, etal. MiR-145 directly targets p70S6K1in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012;40(2):761-774.
10. Speranza MC, Frattini V, Pisati F, etal. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012;3(7):723-734.
11. Yun SJ, Jeong P, Kim WT, etal. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012;41(5):1871-1878.
12. Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 2012;28(5):1831-1837.
13. Bauer KM, Hummon AB. Effects of the miR-143/-145microRNA cluster on the colon cancer proteome and transcriptome. J Proteome Res. 2012;11(9):4744-4754.
14. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012;5:164.
15. Gao P, Xing AY, Zhou GY, etal. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013;32(4):491-501.
16. Lu Y, Govindan R, Wang L, etal. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046-1054.
17. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013;32(1):61-69.
18. Fan L, Wu Q, Xing X, Wei Y, Shao Z. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 2012;44(5):407-414.
19. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735-739.
20. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882-891.
21. Kim SJ, Oh JS, Shin JY, etal. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release. 2011;155(3):427-434.
22. Wang Z, Zhang X, Yang Z, etal. MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. Biochem Biophys Res Commun. 2012;427(3):444-449.
23. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145modulates KRAS signaling through downregulation of multiple targets. Oncogene. 2013;32(20):2576-2585.
24. Sachdeva M, Liu Q, Cao J, Lu Z, Mo YY. Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 2012;40(14):6683-6692.
25. Schaefer A, Jung M, Mollenkopf HJ, etal. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166-1176.
26. Wang CJ, Zhou ZG, Wang L, etal. Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer. Dis Markers. 2009;26(1):27-34.
27. Liu R, Liao J, Yang M, etal. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One. 2012;7(3):e33987.